partitioned survival model

Research Reports

Cost-Effectiveness of Afatinib Versus Erlotinib in the First-line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With EGFR Exon 19 Deletion Mutations

05/06/2016

Rakesh Luthra , MS;

Jonathan Graham , BS;

Stephanie Earnshaw , PhD;

Rohit Borker , PhD;

Jonathan Lim , BS, MS, MSc;

Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...

...

05/06/2016

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

March 23 ⁠–⁠ March 24

April 27 ⁠–⁠ April 28

Great Debates & Updates in Diabetic Foot

November 30 ⁠–⁠ December 2

November 27 ⁠–⁠ November 29

December 12 ⁠–⁠ December 13

May 13 ⁠–⁠ May 14

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

partitioned survival model

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products